LENZ THERAPEUTICS, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
LENZ THERAPEUTICS, INC. (LENZ) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-03-24
- LENZ THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $0.00.
- LENZ THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $0.00.
- LENZ THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-12-31 was -$89.00K.
- LENZ THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-09-30 was -$13.00K.
- LENZ THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- LENZ THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $1.12M, a 487.37% increase from fiscal 2023.
- LENZ THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $190.00K.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $0.00 derived: sum of 2 quarters · filed 2026-03-24 | $0.00 10-K · filed 2026-03-24 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | ||
| 2025-06-30 | $0.00 10-Q · filed 2025-07-30 | |||
| 2024-12-31 | -$89.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$102.00K derived: sum of 2 quarters · filed 2026-03-24 | $823.00K derived: sum of 3 quarters · filed 2026-03-24 | $1.12M 10-K · filed 2026-03-24 |
| 2024-09-30 | -$13.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $912.00K derived: sum of 2 quarters · filed 2025-11-05 | $1.21M 10-Q · filed 2025-11-05 | $1.21M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $925.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | $1.22M 10-Q · filed 2025-07-30 | $1.22M derived: sum of 3 quarters · filed 2025-07-30 | $1.22M derived: sum of 4 quarters · filed 2025-07-30 |
| 2024-03-31 | $293.00K 10-Q · filed 2024-05-08 | $293.00K derived: sum of 2 quarters · filed 2025-03-19 | $293.00K derived: sum of 3 quarters · filed 2025-03-19 | $483.00K derived: sum of 4 quarters · filed 2025-03-19 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $0.00 derived: sum of 2 quarters · filed 2025-03-19 | $190.00K derived: sum of 3 quarters · filed 2025-03-19 | $190.00K 10-K · filed 2025-03-19 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $190.00K derived: sum of 2 quarters · filed 2024-11-06 | $190.00K 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $190.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $190.00K 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |